They were first described in laryngeal cancer over 30 years ago, when studies showed an increase in the reactivity of sex hormone receptors, specifically ERα, in malignant laryngeal tissue compared to adjacent healthy tissue [6,12,13], and many studies have shown that laryngeal cancers respond to estrogen [14,15,16]. The gene discussed is ESR1; the disease is laryngeal carcinoma.